SEC Form 4 · accession 0001209191-18-048681
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Wilhelmus Cm Groenhuysen
Officer — Chief Financial Officer
Period of report
Aug 24, 2018
Accepted (ET)
Aug 28, 2018 · 4:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Aug 24, 2018 | S | 25,274 | $40.00 | D | 47,397 | D | |
| Ordinary SharesF1 | Aug 24, 2018 | S | 200 | $40.025 | D | 47,197 | D | |
| Ordinary SharesF1 | Aug 24, 2018 | S | 100 | $40.05 | D | 47,097 | D | |
| Ordinary SharesF2 | Aug 27, 2018 | S | 9,973 | $40.0284 | D | 37,124 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen.
- F2On August 27, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 9,973 shares in multiple trades at prices ranging from $40.00 to $40.20. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.